ArticleFrontiers in oncology2022

Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer.

Josephine Louella Feliciano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.